C9101 HCPCS Level II code: Injection, oliceridine, 0.1 mg
C9101 is the HCPCS code for “Injection, oliceridine, 0.1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
C9101Injection, oliceridine, 0.1 mg
Short description: Inj, oliceridine 0.1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with C9101 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Medical/surgical supplies
- Coverage statute
- 1833(t)
- Added
- Oct 1, 2022
Where C9101 sits
- 1C codesOutpatient prospective payment system
- 2Active code C9101Injection, oliceridine, 0.1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code C9101 mean?
C9101 is the HCPCS code for “Injection, oliceridine, 0.1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover C9101?
CMS lists C9101’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9101
All C codesC9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mgC9094Inj, sutimlimab-jome, 10 mgC9095Inj, tebentafusp-tebn, 1 mcgC9096Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramC9097Inj, faricimab-svoa, 0.1 mgC9098Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures…C9113Injection, pantoprazole sodium, per vialC9121Injection, argatroban, per 5 mgC9122Mometasone furoate sinus implant, 10 micrograms (sinuva)C9132Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activityC9133Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.C9134Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.